 HIV Antibodies
"HIV Antibodies" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies reactive with HIV ANTIGENS.
| Descriptor ID |
D015483
|
| MeSH Number(s) |
D12.776.124.486.485.114.254.150.440 D12.776.124.790.651.114.254.150.440 D12.776.377.715.548.114.254.150.440
|
| Concept/Terms |
HIV Antibodies- HIV Antibodies
- Antibodies, HIV
- HIV Associated Antibodies
- Antibodies, HIV Associated
- HIV-Associated Antibodies
- Antibodies, HIV-Associated
- HTLV III Antibodies
- Antibodies, HTLV III
- HTLV III LAV Antibodies
- T-Lymphotropic Virus Type III Antibodies, Human
- HTLV-III-LAV Antibodies
- Antibodies, HTLV-III-LAV
- LAV Antibodies
- Antibodies, LAV
- Lymphadenopathy Associated Antibodies
- Antibodies, Lymphadenopathy Associated
- Lymphadenopathy-Associated Antibodies
- Antibodies, Lymphadenopathy-Associated
- T Lymphotropic Virus Type III Antibodies, Human
- AIDS Antibodies
- Antibodies, AIDS
- HTLV-III Antibodies
- Antibodies, HTLV-III
|
Below are MeSH descriptors whose meaning is more general than "HIV Antibodies".
Below are MeSH descriptors whose meaning is more specific than "HIV Antibodies".
This graph shows the total number of publications written about "HIV Antibodies" by people in this website by year, and whether "HIV Antibodies" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 | | 1995 | 0 | 2 | 2 | | 1999 | 0 | 1 | 1 | | 2001 | 1 | 0 | 1 | | 2003 | 1 | 0 | 1 | | 2005 | 0 | 1 | 1 | | 2006 | 0 | 2 | 2 | | 2007 | 1 | 0 | 1 | | 2010 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2012 | 2 | 0 | 2 | | 2013 | 1 | 0 | 1 | | 2014 | 4 | 2 | 6 | | 2015 | 0 | 1 | 1 | | 2017 | 3 | 1 | 4 | | 2018 | 1 | 2 | 3 | | 2019 | 1 | 2 | 3 | | 2020 | 2 | 0 | 2 | | 2021 | 2 | 2 | 4 | | 2022 | 0 | 3 | 3 | | 2023 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "HIV Antibodies" by people in Profiles.
-
Dugdale CM, Ufio O, Alba C, Permar SR, Stranix-Chibanda L, Cunningham CK, Fouda GG, Myer L, Weinstein MC, Leroy V, McFarland EJ, Freedberg KA, Ciaranello AL. Cost-effectiveness of broadly neutralizing antibody prophylaxis for HIV-exposed infants in sub-Saharan African settings. J Int AIDS Soc. 2023 01; 26(1):e26052.
-
Faris JG, Orbidan D, Wells C, Petersen BK, Sprenger KG. Moving the needle: Employing deep reinforcement learning to push the boundaries of coarse-grained vaccine models. Front Immunol. 2022; 13:1029167.
-
Lucier A, Fong Y, Li SH, Dennis M, Eudailey J, Nelson A, Saunders K, Cunningham CK, McFarland E, McKinney R, Moody MA, LaBranche C, Montefiori D, Permar SR, Fouda GG. Frequent Development of Broadly Neutralizing Antibodies in Early Life in a Large Cohort of Children With Human Immunodeficiency Virus. J Infect Dis. 2022 05 16; 225(10):1731-1740.
-
Conti S, Ovchinnikov V, Faris JG, Chakraborty AK, Karplus M, Sprenger KG. Multiscale affinity maturation simulations to elicit broadly neutralizing antibodies against HIV. PLoS Comput Biol. 2022 04; 18(4):e1009391.
-
Nalwoga A, Roshan R, Moore K, Marshall V, Miley W, Labo N, Nakibuule M, Cose S, Rochford R, Newton R, Whitby D. Kaposi's sarcoma-associated herpesvirus T cell responses in HIV seronegative individuals from rural Uganda. Nat Commun. 2021 12 16; 12(1):7323.
-
McFarland EJ, Cunningham CK, Muresan P, Capparelli EV, Perlowski C, Morgan P, Smith B, Hazra R, Purdue L, Harding PA, Theron G, Mujuru H, Agwu A, Purswani M, Rathore MH, Flach B, Taylor A, Lin BC, McDermott AB, Mascola JR, Graham BS. Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1) Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants. J Infect Dis. 2021 12 01; 224(11):1916-1924.
-
Wiredja D, Ritchie TA, Tam G, Hogan CA, Pinsky B, Shi RZ. Performance evaluation and optimized reporting workflow for HIV diagnostic screening and confirmatory tests in a low prevalence setting. J Clin Virol. 2021 12; 145:105020.
-
Taylor RA, Xiao S, Carias AM, McRaven MD, Thakkar DN, Ara?nga M, Allen EJ, Rogers KA, Kumarapperuma SC, Gong S, Fought AJ, Anderson MR, Thomas Y, Schneider JR, Goins B, Fox P, Villinger FJ, Ruprecht RM, Hope TJ. PET/CT targeted tissue sampling reveals virus specific dIgA can alter the distribution and localization of HIV after rectal exposure. PLoS Pathog. 2021 06; 17(6):e1009632.
-
Edupuganti S, Mgodi N, Karuna ST, Andrew P, Rudnicki E, Kochar N, deCamp A, De La Grecca R, Anderson M, Karg C, Tindale I, Greene E, Broder GB, Lucas J, Hural J, Gallardo-Cartagena JA, Gonzales P, Frank I, Sobieszczyk M, Gomez Lorenzo MM, Burns D, Anderson PL, Miner MD, Ledgerwood J, Mascola JR, Gilbert PB, Cohen MS, Corey L. Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody. J Acquir Immune Defic Syndr. 2021 05 01; 87(1):671-679.
-
Zhang P, Kwon AL, Guzzo C, Liu Q, Schmeisser H, Miao H, Lin Y, Cimbro R, Huang J, Connors M, Schmidt SD, Dolan MA, Armstrong AA, Lusso P. Functional Anatomy of the Trimer Apex Reveals Key Hydrophobic Constraints That Maintain the HIV-1 Envelope Spike in a Closed State. mBio. 2021 03 30; 12(2).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|